A Phase II Study of Surufatinib Combined With Camrelizumab and mFOLFOX6 as Second-line Treatment for Advanced PRAD

StatusUnknown
PhasePhase 2
Started

Record status This record was last updated May 8, 2024 (before its estimated January 1, 2025 completion). Its status may not reflect the trial's current state.

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Track this trial
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Changed Registry marked status Unknown (sponsor has not verified the record since May 2024); last known: Not Yet Recruiting
  2. Start date: Mar 22, 2024 to May 22, 2024
    • Interventions: Surufatinib in combination with Caralizumab and mFOLFOX6 (Drug) to Surufatinib 250mg/d qd once daily (Drug)
    • Study title revised
    v2
  3. Study First Submitted
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
To preliminarily evaluate whether there is a survival benefit of surufatinib combined with camrelizumab and mFOLFOX6 as the second-line treatment for advanced pancreatic cancer, and to explore the feasibility of second-line and post-line treatment for advanced pancreatic cancer
Trial Details
NCT Number NCT06329947
Lead Sponsor Rui-hua Xu, MD, PhD
Conditions
(from sponsor)		 Advanced Pancreatic Cancer
Enrollment 37 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov